Option chain shows key data for Genprex's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Genprex.

Genprex (NASDAQ:GNPX) Stock, Option Chain

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Exclusives

Trading Ideas

AAPL

AMZN

DRUG

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

movers image

News

Pre-Market Outlook

Markets

Movers

ANRO

APVO

CHSN

CNSP

DBGI

DBVT

ENPH

ENSC

FAMI

MBIO

PHUN

PIXY

XXII

ZPTA

Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket

Wall-Street-ai7-1

Equities

Eurozone

Commodities

Intraday Update

ALPS ETF Trusthen & Steers Global Realty Majors ETF

INAB

JCSE

SGMO

Dow Falls Over 150 Points; General Motors Tops Q3 Views

Genprex Inc

JUNS

Jupiter Neurosciences Shares Halted, Stock Now Up 89.50%

<p>Providing a diverse range of perspectives from bullish to bearish, 21 analysts have published ratings on Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) in the last three months.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">14</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $82.67, a high estimate of $120.00, and a low estimate of $64.00. This current average represents a 31.27% decrease from the previous average price target of $120.28. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245288_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Dollar Tree among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$92.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$65.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Brandon Fletcher</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>-</td>
</tr>
<tr>
<td>Karen Short</td>
<td>Melius Research</td>
<td>Announces</td>
<td>Hold</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>John Heinbockel</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$64.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Edward Kelly</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Bradley Thomas</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Kelly Bania</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$68.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$81.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Peter Keith</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$78.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Hold</td>
<td>$65.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dollar Tree. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dollar Tree compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Dollar Tree's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DLTR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dollar Tree analyst ratings.</strong></a></p>
<h2>Discovering Dollar Tree: A Closer Look</h2>
<p>Dollar Tree operates discount stores across the United States and Canada, with over 8,600 shops under its namesake banner and nearly 7,800 under Family Dollar. About 47% of Dollar Tree's sales in fiscal 2023 were composed of consumables (including food, health and beauty, and cleaning products), around 45% from variety items (including toys and homewares), and over 5% from seasonal items. The Dollar Tree banner sells most of its merchandise at the $1.25 price point and positions its stores in well-populated suburban markets. Conversely, Family Dollar primarily sells consumable merchandise (80% of the banner's sales) at prices below $10. About two-thirds of Family Dollar's stores are located in urban and suburban markets, with the remaining one-third located in rural areas.</p>
<h3>Dollar Tree's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Dollar Tree's revenue growth over a period of 3 months has been noteworthy. As of 31 July, 2024, the company achieved a revenue growth rate of approximately <strong>0.73%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Dollar Tree's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>1.79%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dollar Tree's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>1.8%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Dollar Tree's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.59%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Dollar Tree's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.46</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

DLTR

Cracking The Code: Understanding Analyst Reviews For Dollar Tree

<p>Throughout the last three months, 13 analysts have evaluated Northern Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRS#NASDAQ">NTRS</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $103.62, a high estimate of $115.00, and a low estimate of $82.00. This upward trend is evident, with the current average reflecting a 9.43% increase from the previous average price target of $94.69.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245262_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Northern Trust. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$113.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Carrier</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$103.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$103.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$108.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$97.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$82.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$94.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Northern Trust. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Northern Trust compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Northern Trust's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Northern Trust's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTRS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Northern Trust analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Northern Trust</h2>
<p>Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of September 2024, Northern Trust had assets under custody or administration of $17.4 trillion and assets under management of $1.6 trillion.</p>
<h3>Unraveling the Financial Story of Northern Trust</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Northern Trust's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>14.02%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Northern Trust's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>22.61%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Northern Trust's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.77%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Northern Trust's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.28%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.16</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTRS

Beyond The Numbers: 13 Analysts Discuss Northern Trust Stock

<p>Across the recent three months, 5 analysts have shared their insights on AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated AGCO and provided 12-month price targets. The average target is $107.6, accompanied by a high estimate of $127.00 and a low estimate of $99.00. A 4.14% drop is evident in the current average compared to the previous average price target of $112.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245253_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of AGCO by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angel Castillo</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$101.00</td>
<td>-</td>
</tr>
<tr>
<td>Jerry Revich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$99.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$111.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Kyle Menges</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$118.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AGCO. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AGCO compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of AGCO's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AGCO's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AGCO/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on AGCO analyst ratings.</strong></a></p>
<h2>Discovering AGCO: A Closer Look</h2>
<p>Agco is a global manufacturer of agricultural equipment. The company has five core brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements to grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes about 3,100 dealer and distribution locations. Agco offers retail and wholesale financing to customers through its joint venture with Rabobank, a European food- and agriculture-focused bank.</p>
<h3>AGCO's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, AGCO faced challenges, resulting in a decline of approximately <strong>-24.78%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> AGCO's net margin is impressive, surpassing industry averages. With a net margin of <strong>1.15%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> AGCO's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.73%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> AGCO's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.22%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.0</strong>, AGCO faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AGCO

What 5 Analyst Ratings Have To Say About AGCO

<p>High-rolling investors have positioned themselves bearish on Vale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VALE often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 11 options trades for Vale. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 36% bullish and 54% bearish. Among all the options we identified, there was one put, amounting to $26,550, and 10 calls, totaling $1,246,700.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $1.0 to $10.0 for Vale over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Vale stands at 5179.0, with a total volume reaching 3,140.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Vale, situated within the strike price corridor from $1.0 to $10.0, throughout the last 30 days.</p>
<h3>Vale Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245241_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VALE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.95</td>
<td>$8.55</td>
<td>$8.75</td>
<td>$1.00</td>
<td>$175.0K</td>
<td>1.2K</td>
<td align="right">720</td>
</tr>
<tr>
<td>VALE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.75</td>
<td>$8.05</td>
<td>$8.75</td>
<td>$1.00</td>
<td>$175.0K</td>
<td>2.2K</td>
<td align="right">400</td>
</tr>
<tr>
<td>VALE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.75</td>
<td>$8.05</td>
<td>$8.75</td>
<td>$1.00</td>
<td>$175.0K</td>
<td>2.2K</td>
<td align="right">200</td>
</tr>
<tr>
<td>VALE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$9.4</td>
<td>$8.5</td>
<td>$8.7</td>
<td>$1.00</td>
<td>$173.9K</td>
<td>1.2K</td>
<td align="right">200</td>
</tr>
<tr>
<td>VALE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$9.4</td>
<td>$8.05</td>
<td>$8.7</td>
<td>$1.00</td>
<td>$173.9K</td>
<td>2.2K</td>
<td align="right">600</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vale</h3>
<p>Vale is a large global miner and the world's largest producer of iron ore and pellets. In recent years the company has sold noncore assets such as its fertilizer, coal, and steel operations to concentrate on iron ore, nickel, and copper. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets. The base metals division is much smaller, consisting of nickel mines and smelters along with copper mines producing copper in concentrate. In 2024, Vale sold a minority 10% stake in energy transition metals, its base metals business, likely the first step in separating base metals and iron ore.</p>
<p>After a thorough review of the options trading surrounding Vale, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Vale Standing Right Now?</h3>
<ul>
<li>With a volume of 14,709,289, the price of VALE is down -0.51% at $9.74. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 79 days.</li>
</ul>
<h3>What Analysts Are Saying About Vale</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $12.75.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Scotiabank persists with their Sector Perform rating on Vale, maintaining a target price of $14.<br />
&#x2A; In a cautious move, an analyst from UBS downgraded its rating to Neutral, setting a price target of $11. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vale with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

VALE

Vale's Options: A Look at What the Big Money is Thinking

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>AST SpaceMobile</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ASTS, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 17 options trades for <strong>AST SpaceMobile</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 64% bullish and 29%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $35,412, and 16, calls, for a total amount of $707,369.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $12.5 to $35.0 for AST SpaceMobile over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for AST SpaceMobile's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AST SpaceMobile's whale activity within a strike price range from $12.5 to $35.0 in the last 30 days. </p>
<h3>AST SpaceMobile 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245236_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$4.9</td>
<td>$20.00</td>
<td>$96.0K</td>
<td>11.8K</td>
<td align="right">215</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.8</td>
<td>$8.6</td>
<td>$8.76</td>
<td>$15.00</td>
<td>$70.9K</td>
<td>6.7K</td>
<td align="right">125</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/03/25</td>
<td>$3.2</td>
<td>$2.65</td>
<td>$2.85</td>
<td>$23.00</td>
<td>$57.0K</td>
<td>40</td>
<td align="right">200</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.9</td>
<td>$20.00</td>
<td>$49.0K</td>
<td>11.8K</td>
<td align="right">315</td>
</tr>
<tr>
<td>ASTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.35</td>
<td>$2.2</td>
<td>$2.33</td>
<td>$23.00</td>
<td>$46.9K</td>
<td>567</td>
<td align="right">400</td>
</tr>
</tbody>
</table>
</p>
<h3>About AST SpaceMobile</h3>
<p>AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers and finally bringing broadband to the billions who remain unconnected. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.</p>
<p>Having examined the options trading patterns of AST SpaceMobile, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>AST SpaceMobile's Current Market Status</h3>
<ul>
<li>With a trading volume of 3,175,276, the price of ASTS is down by -1.29%, reaching $22.92.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 118 days from now.</li>
</ul>
<h3>What The Experts Say On AST SpaceMobile</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $37.85.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for AST SpaceMobile, targeting a price of $44.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for AST SpaceMobile, targeting a price of $31. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AST SpaceMobile options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


ASTS

AST SpaceMobile's Options: A Look at What the Big Money is Thinking

<p>Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $164.33, a high estimate of $194.00, and a low estimate of $145.00. A 3.83% drop is evident in the current average compared to the previous average price target of $170.88. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245233_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Hess among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$185.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$154.00</td>
<td>$149.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$167.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$160.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$173.00</td>
<td>$192.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$194.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hess. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hess compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Hess's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Hess's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HES/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Hess analyst ratings.</strong></a></p>
<h2>All You Need to Know About Hess</h2>
<p>Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2023, the company reported net proved reserves of 1.4 billion barrels of oil equivalent. Net production averaged 391 thousand barrels of oil equivalent per day in 2023, at a ratio of 74% oil and natural gas liquids and 26% natural gas.</p>
<h3>Hess's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Hess's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>13.96%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Hess's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>15.61%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Hess's ROE excels beyond industry benchmarks, reaching <strong>4.67%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Hess's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.91%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.88</strong>, caution is advised due to increased financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Beyond The Numbers: 9 Analysts Discuss Hess Stock

<p><strong>Ooma</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-12-04. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Ooma will report an <strong>earnings per share</strong> (EPS) of $0.15. </p>
<p>The market awaits Ooma's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.02, leading to a 24.94% increase in the share price the following trading session.</p>
<p>Here's a look at Ooma's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.13</td>
<td>0.11</td>
<td>0.12</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.15</td>
<td>0.14</td>
<td>0.13</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>25.0%</td>
<td>8.0%</td>
<td>-12.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245232_0.png" alt="eps graph" /></p>
<h3>Market Performance of Ooma's Stock</h3>
<p>Shares of Ooma were trading at $14.75 as of December 02. Over the last 52-week period, shares are up 37.67%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analyst Opinions on Ooma</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Ooma.</p>
<p>Ooma has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $16.25, the consensus suggests a potential 10.17% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of 8x8, CS Disco and Mitek Systems, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>8x8 is maintaining an Buy status according to analysts, with an average 1-year price target of $2.95, indicating a potential 80.0% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for CS Disco, with an average 1-year price target of $7.0, indicating a potential 52.54% downside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Mitek Systems, with an average 1-year price target of $9.5, indicating a potential 35.59% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for 8x8, CS Disco and Mitek Systems, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ooma</td>
<td>Buy</td>
<td>9.90%</td>
<td>$38.70M</td>
<td>-2.62%</td>
</tr>
<tr>
<td>8x8</td>
<td>Buy</td>
<td>-2.16%</td>
<td>$123.17M</td>
<td>-13.57%</td>
</tr>
<tr>
<td>CS Disco</td>
<td>Buy</td>
<td>3.79%</td>
<td>$26.53M</td>
<td>-5.42%</td>
</tr>
<tr>
<td>Mitek Systems</td>
<td>Neutral</td>
<td>4.43%</td>
<td>$38.49M</td>
<td>0.10%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Ooma ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. Ooma is at the bottom for Return on Equity.</p>
<h3>About Ooma</h3>
<p>Ooma Inc is a communications services company. It is a smart software-as-a-service ("SaaS") and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. Ooma generates revenues from the sale of subscriptions and other services.</p>
<h3>Understanding the Numbers: Ooma's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Ooma displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately <strong>9.9%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Ooma's net margin excels beyond industry benchmarks, reaching <strong>-3.33%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-2.62%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Ooma's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-1.39%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Ooma's debt-to-equity ratio is below the industry average at <strong>0.3</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/OOMA/earnings"><strong>To track all earnings releases for Ooma visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

OOMA

Ooma's Earnings Outlook

<p>Financial giants have made a conspicuous bullish move on MongoDB. Our analysis of options history for MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 41% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $185,400, and 8 were calls, valued at $635,840.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $260.0 to $350.0 for MongoDB during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for MongoDB options trades today is 659.3 with a total volume of 614.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for MongoDB's big money trades within a strike price range of $260.0 to $350.0 over the last 30 days.</p>
<h3>MongoDB Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245231_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MDB</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$17.25</td>
<td>$16.4</td>
<td>$16.9</td>
<td>$350.00</td>
<td>$253.5K</td>
<td>870</td>
<td align="right">1</td>
</tr>
<tr>
<td>MDB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$25.0</td>
<td>$24.1</td>
<td>$25.0</td>
<td>$340.00</td>
<td>$125.0K</td>
<td>713</td>
<td align="right">51</td>
</tr>
<tr>
<td>MDB</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$31.2</td>
<td>$29.35</td>
<td>$30.3</td>
<td>$330.00</td>
<td>$75.7K</td>
<td>275</td>
<td align="right">25</td>
</tr>
<tr>
<td>MDB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$22.8</td>
<td>$22.7</td>
<td>$22.8</td>
<td>$330.00</td>
<td>$57.0K</td>
<td>1.2K</td>
<td align="right">45</td>
</tr>
<tr>
<td>MDB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$17.25</td>
<td>$16.9</td>
<td>$16.9</td>
<td>$350.00</td>
<td>$55.7K</td>
<td>870</td>
<td align="right">151</td>
</tr>
</tbody>
</table>
</p>
<h3>About MongoDB</h3>
<p>Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.</p>
<h3>Present Market Standing of MongoDB</h3>
<ul>
<li>Currently trading with a volume of 296,638, the MDB's price is down by -0.36%, now at $323.99. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About MongoDB</h3>
<p>A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $390.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on MongoDB with a target price of $345.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on MongoDB with a target price of $425.<br />
&#x2A; An analyst from Loop Capital has decided to maintain their Buy rating on MongoDB, which currently sits at a price target of $400. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for MongoDB with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


MongoDB Unusual Options Activity For December 03

<p>Across the recent three months, 4 analysts have shared their insights on Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.5, with a high estimate of $22.00 and a low estimate of $14.00. This current average reflects an increase of 15.14% from the previous average price target of $14.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245224_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Ocular Therapeutix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ocular Therapeutix. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ocular Therapeutix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Ocular Therapeutix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ocular Therapeutix's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OCUL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ocular Therapeutix analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Ocular Therapeutix: A Closer Look</h2>
<p>Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.</p>
<h3>Ocular Therapeutix: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Ocular Therapeutix showcased positive performance, achieving a revenue growth rate of <strong>2.28%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Ocular Therapeutix's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-236.58%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Ocular Therapeutix's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-10.0%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Ocular Therapeutix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-7.24%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Ocular Therapeutix's debt-to-equity ratio is below the industry average. With a ratio of <b>0.21</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OCUL

Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts

<p>23 analysts have expressed a variety of opinions on Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">12</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Comerica, presenting an average target of $67.04, a high estimate of $85.00, and a low estimate of $51.00. This upward trend is apparent, with the current average reflecting a 13.13% increase from the previous average price target of $59.26.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733245210_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Comerica. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$73.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$67.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$70.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$51.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$66.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$64.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$66.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Peter Winter</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Comerica. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Comerica compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Comerica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Comerica's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CMA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Comerica analyst ratings.</strong></a></p>
<h2>Get to Know Comerica Better</h2>
<p>With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.</p>
<h3>A Deep Dive into Comerica's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Comerica faced challenges, resulting in a decline of approximately <strong>-9.49%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Comerica's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>21.82%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.78%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.22%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Comerica's debt-to-equity ratio is below the industry average at <strong>0.97</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For Comerica

<p><strong>Chewy Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) could show continued strength and subscription revenue when reporting third-quarter financials <a href="https://www.benzinga.com/earnings">before the market opens Wednesday.</a></p>
<p><strong>Earnings Estimates:</strong> Analysts expect the online retailer to report third-quarter revenue of $2.89 billion. That&#8217;s up from $2.74 billion reported in last year's third quarter, according to data <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent120224&amp;t=be2bearmibe3na1">from Benzinga Pro.</a></p>
<p>Chewy missed analyst estimates for revenue in the last quarter while beating estimates in seven of the last 10 quarters.</p>
<p>Analysts expect third-quarter earnings per share of 8 cents, down from 15 cents per share in last year's third quarter. The company has beaten analyst estimates for earnings per share in 10 straight quarters.</p>
<p>If the company reports earnings of eight cents per share it would be the lowest quarterly total in seven quarters.</p>
<p>Guidance<a href="https://www.benzinga.com/news/earnings/24/08/40599759/pet-supply-retailer-chewys-q2-earnings-profit-edges-out-expectation-sales-per-active-customer-hits-"> from the company</a> calls for third-quarter revenue to be in&nbsp; range of $2.84 billion to $2.86 billion.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/news/24/10/41614177/roaring-kitty-puts-chewy-stock-in-the-litter-box-gamestop-shares-move-higher-after-hours">Roaring Kitty Puts Chewy Stock In The Litter Box</a></strong></p>
<p><strong>What Analysts Are Saying:</strong>  Bank of America analyst Curtis Nagle upgraded Chewy from Underperform to Buy. He raised the price target from $24 to $40.</p>
<p>The analyst said investors underestimate Chewy&#8217;s expense discipline, which could lead to <a href="https://www.benzinga.com/24/11/42097829/roaring-kitty-ditched-chewy-analyst-says-you-should-adopt-the-stock-with-path-to-pawsitive-growth">earnings growth</a>.</p>
<p>&#8220;Stabilizing industry trends lay path to pawsitive growth,&#8221; Nagle said.</p>
<p>Nagle said animal shelters are taking in a large number of pets, but adoption trends have improved since the start of 2024.</p>
<p>Pet spending also appears to have bottomed since being negative year-over-year earlier this year, the analyst added.</p>
<p>Chewy&#8217;s website traffic jumped 6% year over year in the third quarter compared to down 11% year over year in the first quarter. That could support market share gains and a higher customer count, Nagle added.</p>
<p>The improving industry data could lead to stronger earnings leverage for Chewy, something Nagle said is being underestimated regarding the stock.</p>
<p>The analyst said Chewy&#8217;s subscription-like model should command a premium and the company&#8217;s low exposure to discretionary categories minimizes the impact for increased Chinese tariffs.</p>
<p>Nagle predicts that Chewy can beat the third-quarter Street estimate of 50,000 net adds for active customers, given the pet industry trends and website traffic. The analyst notes that over the last 10 quarters, the active customer count has been a leading indicator of which way the stock will move.</p>
<p>JPMorgan analyst Doug Anmuth expects Chewy to continue to execute with stable industry trends ahead for the company. He reiterated an Overweight rating and raised the price target from $33 to $37 recently.</p>
<p>Product improvements, better execution and stabilizing trends lead to the price target increase, Anmuth said.</p>
<p>"We believe pet is a growing and highly attractive category that is early in the shift online, and, in our view, Chewy is well positioned as the leader in online pet with a ~33% market share," Anmuth said.</p>
<p>Anmuth said the shift to online sales for the pet care sector, growth of pet health for Chewy and international expansion can help the company.</p>
<p>"We remain bullish on CHWY's category positioning, improving profitability, and efforts to diversify revenue into healthcare."</p>
<p>Chewy's Autoship subscription program is called a "key competitive advantage" by the analyst.</p>
<p>Here are other <a href="https://www.benzinga.com/quote/CHWY/analyst-ratings">analyst ratings for Chewy</a> and their price targets:</p>
<ul>
<li>Piper Sandler: Maintained an Overweight rating, raised price target from $35 to $40</li>
<li>Morgan Stanley: Maintained an Overweight rating, raised price target from $33 to $36</li>
<li>Baird: Maintained an Outperform rating, raised price target from $35 to $40</li>
<li>Deutsche Bank: Maintained a Hold rating, raised price target from $24 to $28</li>
<li>Barclays: Maintained an Overweight rating, raised price target from $34 to $40</li>
</ul>
<p><strong>Price Action: </strong>Chewy stock is down 1% to $33.36 on Tuesday versus a 52-week trading range of $14.68 to $39.10. Chewy stock is up 49% year-to-date in 2024.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41402089/goldman-sachs-highlights-20-top-short-squeeze-opportunities-for-q3-earnings-season">Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


CHWY

Chewy Q3 Earnings Preview: Analyst Says Company 'Well Positioned As The Leader' In Online Pet Supplies

<p>HC Wainwright &amp; Co.  analyst Mike Colonnese   reiterates HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and maintains $8 price target.</p>


Price Target

Reiteration

HIVE

HC Wainwright & Co. Reiterates Buy on HIVE Digital Technologies, Maintains $8 Price Target

<p><i>New Amazon EC2 Trn2 instances, featuring AWS's newest Trainium2 AI chip, offer 30-40% better price performance than the current generation of GPU-based EC2 instances</i></p>
<p><i>New Trn2 UltraServers use ultra-fast NeuronLink interconnect to connect four Trn2 servers together into one giant server, enabling the fastest training and inference on AWS for the world's largest models</i></p>
<p>&nbsp;</p>


AWS Announces Availability Of Trainium2-Powered Amazon Elastic Compute Cloud Instances

<p><i>Amazon S3 Tables deliver up to 3x faster query performance and up to 10x higher transactions per second for analytics workloads; Amazon S3 Metadata delivers queryable object metadata in near real time to search, organize, and augment data to accelerate data discovery</i></p>


Amazon Announces New Amazon Simple Storage Services Features That Make S3 First Cloud Object Store With Fully-Managed Support For Apache Iceberg

<p><strong>BlackRock, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) shares are trading higher today. The company disclosed a definitive agreement to acquire <strong>HPS Investment <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42284824/blackrock-to-acquire-hps-investment-partners-to-deliver-integrated-solutions-across-public-and-pri" rel="noreferrer noopener">Partners</a></strong><a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42284824/blackrock-to-acquire-hps-investment-partners-to-deliver-integrated-solutions-across-public-and-pri" rel="noreferrer noopener"> for around $12 billion</a>.</p>
<p>The acquisition will be fully paid in BlackRock equity, issued as &#8220;SubCo Units&#8221; by a wholly-owned subsidiary of BlackRock, exchangeable one-for-one into BlackRock common stock.</p>
<p>A portion of the consideration will be paid at closing, with approximately 9.2 million SubCo Units paid at the same time.</p>
<p>About 25% (2.9 million SubCo Units) will be deferred for five years, contingent on post-closing conditions. Additionally, up to 1.6 million SubCo Units may be earned based on financial performance milestones. The total deal could result in the issuance of approximately 13.7 million BlackRock shares.</p>
<p>The acquisition will integrate BlackRock&#8217;s extensive corporate and asset owner relationships with HPS&#8217;s expertise in diversified origination and capital flexibility. This transaction strengthens BlackRock&#8217;s offerings for insurance clients.</p>
<p>Together, the combined private credit franchise with ~$220 billion in client assets and BlackRock&#8217;s $3 trillion public fixed-income business will offer clients comprehensive public and private income solutions across their entire portfolios.</p>
<p>The combined platform will offer end-to-end capabilities in credit solutions, asset-based finance, real estate, private placements, and CLOs.</p>
<p>The acquisition positions BlackRock as a full-service, fiduciary provider of public and private asset management and <a target="_blank" href="https://www.benzinga.com/24/11/42227693/blackrock-set-to-acquire-private-credit-manager-hps-for-12b-report" rel="noreferrer noopener">technology solutions for the insurance sector.</a></p>
<p>As part of the transaction, BlackRock plans to retire or refinance approximately $400 million of existing HPS debt. The deal is not expected to significantly impact BlackRock&#8217;s leverage profile.</p>
<p>The company expects to increase private markets fee-paying AUM and management fees by 40% and 35%, respectively, and be modestly accretive to BlackRock&#8217;s as-adjusted earnings <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">per share in the first full year post-close</a>.</p>
<p>The transaction is expected to close in mid-2025, subject to regulatory approvals and customary closing conditions. Notably, BlackRock projects the private debt market to surpass $4.5 trillion by 2030.</p>
<p>Laurence D. Fink, BlackRock Chairman and CEO, said, &#8221;With GIP, and now HPS, we are expanding our private markets capabilities across our comprehensive global platform. Our Aladdin technology, including eFront, and soon Preqin, will make access to private markets simpler and more transparent. These capabilities, together with our global reach, deep relationships, and powerful technology, differentiate our ability to serve clients.&#8221;</p>
<p>As of the third-quarter end, BlackRock&#8217;s <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41288867/blackrocks-steady-climb-q3-earnings-beat-projections-assets-under-management-soars-to-11-5t" rel="noreferrer noopener">total AUM stood at&nbsp;$11.5 trillion</a>.</p>
<p>Investors can gain exposure to the stock via&nbsp;<strong>Fidelity Disruptive Finance ETF</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>) and&nbsp;<strong>Capitol Series Trust The Nightview Fund NITE</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NITE#NYSE">NITE</a>).</p>
<p><strong>Price Action: </strong>BLK shares are up 1.04% at $1,030.72 at the last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42071904/blackrock-sees-renewed-sense-of-optimism-around-bitcoin" target="_blank" rel="noreferrer noopener">BlackRock Sees &#8216;Renewed Sense Of Optimism&#8217; Around Bitcoin</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Large Cap

FDFF

NITE

BlackRock Makes $12 Billion Power Move - Agrees To Acquire HPS To Bolster Private Credit Offerings

<p>Keefe, Bruyette &amp; Woods  analyst Bose George   maintains Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) with a Outperform and raises the price target from $13 to $13.5.</p>


RITM

Keefe, Bruyette & Woods Maintains Outperform on Rithm Capital, Raises Price Target to $13.5

<p>Guggenheim  analyst Michael Morris   reiterates Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Buy and maintains $12.11 price target.</p>


SNAP

Guggenheim Reiterates Buy on Snap, Maintains $12.11 Price Target

<p>Financial giants have made a conspicuous bearish move on Hims &amp; Hers Health. Our analysis of options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) revealed 10 unusual trades.</p>
<p>Delving into the details, we found 20% of traders were bullish, while 70% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $217,948, and 7 were calls, valued at $382,311.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $35.0 for Hims &amp; Hers Health during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Hims &amp; Hers Health's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Hims &amp; Hers Health's substantial trades, within a strike price spectrum from $15.0 to $35.0 over the preceding 30 days.</p>
<h3>Hims &amp; Hers Health Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733244339_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.26</td>
<td>$30.00</td>
<td>$114.1K</td>
<td>8.5K</td>
<td>1.1K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.3</td>
<td>$9.2</td>
<td>$9.3</td>
<td>$25.00</td>
<td>$93.0K</td>
<td>8.5K</td>
<td>153</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.8</td>
<td>$16.6</td>
<td>$16.6</td>
<td>$20.00</td>
<td>$78.0K</td>
<td>3.8K</td>
<td>75</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$12.1</td>
<td>$11.9</td>
<td>$11.96</td>
<td>$24.00</td>
<td>$59.5K</td>
<td>336</td>
<td>54</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/13/24</td>
<td>$0.65</td>
<td>$0.45</td>
<td>$0.55</td>
<td>$27.00</td>
<td>$56.9K</td>
<td>253</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Hims &amp; Hers Health</h3>
<p>Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.</p>
<p>In light of the recent options history for Hims &amp; Hers Health, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Hims &amp; Hers Health Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 8,076,861, with HIMS's price up by 6.42%, positioned at $32.83.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for Hims &amp; Hers Health</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $28.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $21.<br />
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for Hims &amp; Hers Health, targeting a price of $28.<br />
&#x2A; Maintaining their stance, an analyst from Deutsche Bank continues to hold a Hold rating for Hims &amp; Hers Health, targeting a price of $27.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Hims &amp; Hers Health with a target price of $38.<br />
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on Hims &amp; Hers Health, maintaining a target price of $28. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hims &amp; Hers Health options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Hims & Hers Health, Inc. Class A Common Stock

HIMS

Check Out What Whales Are Doing With HIMS

<p>When Saphira and Maurizio Rasti started baking cookies in a borrowed kitchen during the COVID-19 pandemic, they could hardly have imagined it would lead to a $1.6 million valuation on<a href="https://www.benzinga.com/startups/24/09/41030114/the-new-shark-tank-star-replacing-mark-cuban-once-made-a-220-million-blunder-that-grew-his-startup-i"> Shark Tank.</a>&nbsp;</p>
<p>But the Costa Mesa, California-based couple didn't just wow the Sharks – they made them believe in Nowhere Bakery's potential to revolutionize the dessert industry.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks"><strong>this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</strong></a></strong></li>
<li><strong>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></li>
</ul>
<p>The story began in March 2020, just as the world went into lockdown. With $400 to their name, Saphira began baking allergen-friendly cookies and brownies to address her dietary restrictions.&nbsp;</p>
<p>"We're free from dairy, eggs, gluten, soy, refined sugar, sugar alcohols and we're paleo-friendly," she explained. The name "Nowhere Bakery" reflected their humble beginnings – no storefront, no commercial kitchen, just homemade goods hand-delivered to customers.</p>
<p>Fast-forward to 2023 and the couple walked into the Shark Tank with a commercial kitchen, an impressive $770,000 in 2022 revenue and a projected $1 million for 2023. Even with those numbers, the taste of their cookies won over the Sharks.</p>
<p>"This tastes like a real cookie," exclaimed Barbara Corcoran, visibly surprised. "This tastes absolutely delicious." <a href="https://www.benzinga.com/personal-finance/24/09/40714364/survive-anything-kevin-oleary-claims-you-need-5-million-in-savings-heres-how-you-can-reach-that-">Kevin O'Leary</a>, known for his sharp critiques, agreed: "I congratulate you. We've had so many plant-based cookie deals and they all taste like s&#8212;. This is incredible."</p>
<p><strong>See Also: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.26/share!</strong></a></strong></p>
<p>Despite the rave reviews, O'Leary raised concerns about their profit margins. With $770,000 in sales, the company netted just $32,000 in profit, which he attributed to high production costs. He urged the Rastis to partner with a co-packer, offering $200,000 for 20% equity with the condition that they outsource their baking.</p>
<p>"That's a possibility, but right now, we can control everything ourselves," Maurizio countered. Saphira added, "We value the quality and consistency of our treats."</p>
<p>Barbara Corcoran, however, had a different perspective. "Every food product [founder] I've invested in who moved to a co-packer regretted it," she said, sharing a cautionary tale from her portfolio. Corcoran offered $100,000 cash and $100,000 as a line of credit for 15% equity.</p>
<p>Guest Shark Jason Blum, CEO of Blumhouse Productions, proposed teaming up with O'Leary, splitting the investment and equity equally. O'Leary, sold on the idea, noted, "Two Sharks are better than one."</p>
<p><strong>Trending: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold"><strong>create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</strong></a></strong></p>
<p>But the Rastis ultimately struck a deal with Corcoran, negotiating her stake down to 12.5% in exchange for $200,000. "Barbara understands our vision," Saphira said after the deal.</p>
<p>The Rastis' rise mirrors a growing trend in the U.S. food industry. According to a 2020 Meticulous Research report and as cited by Business Insider, the plant-based food market is projected to grow at a compound annual rate of 11.9%, reaching $74.2 billion by 2027.&nbsp;</p>
<p>Meanwhile, according to Meticulous Research, The Clean-Label Ingredients Market is expected to grow at a CAGR of 6.9%, reaching $80.69 billion by 2030. "We started in a friend's kitchen and now we're on a national stage," Maurizio said. "It's time to take Nowhere everywhere."</p>
<p>Following its appearance on Shark Tank, Nowhere Bakery experienced a surge in sales, expanded to 75 U.S. stores and gained further attention through a collaboration with Gwyneth Paltrow. With an estimated annual growth rate of 10%, its current net worth stands at approximately $1.94 million.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</strong></a></strong></li>
<li><strong>If there was a new fund backed by Jeff Bezos offering a</strong><strong> <a href="https://www.benzinga.com/money/arrived-private-credit-fund"><strong>7-9% target yield with monthly dividends would you invest in it</strong></a>?</strong></li>
</ul>


Startups

From a Friend's Kitchen to $1M Sales –'I Congratulate You,' Kevin O'Leary Says After Tasting the Cookies

Warning: GNPX is at high risk of performing badly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Genprex (GNPX) has entered into a Sponsored Research Agreement – SRA – with the University of Michigan Rogel Cancer Center to study TUSC2, the tumo...

Genprex signs two lung cancer research agreements

Genprex (GNPX) announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from ...

Genprex to present positive preclinical data from Reqorsa Gene Therapy study

Genprex (GNPX) announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusiv...

Genprex signs exclusive license agreement with University of Michigan

AKBA

ALLK

CRMD

CYCC

ELAB

IMUX

ONCT

SYRS

Screenshot 2023-07-10 at 5.56.06 PM

Biotech

General

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Cardiol Therapeutics' (NASDAQ: CRDL) CardiolRx™ Addresses Urgent Medical Condition Myocarditis, a Leading Cause of Sudden Cardiac Death see more stocks inside…

Small Cap

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Penny Stocks

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Genprex to Participate in 2024 BIO Europe Conference

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Comments

Genprex

Genprex (GNPX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga